Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 17/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032559 | 0.96 | SLC29A1 (0.49) | SLC29A1MEN1GAAMAPK1KMT2A | |
| SCHEMBL1077004 | 0.88 | SLC29A1 (0.46) | SLC29A1MEN1GAAKMT2A | |
| SCHEMBL12151272 | 0.87 | SLC29A1 (0.43) | SLC29A1MEN1GAAMAPK1KMT2A | |
| SCHEMBL18288099 | 0.84 | SLC29A1 (0.40) | SLC29A1MEN1GAAMAPK1KMT2A | |
| SCHEMBL13295563 | 0.83 | SLC29A1 (0.66) | SLC29A1MEN1GAAMAPK1KMT2A | |
| SCHEMBL15836258 | 0.83 | SLC29A1 (0.45) | SLC29A1MEN1GAAKMT2A | |
| SCHEMBL13597454 | 0.81 | KMT2A (0.55) | SLC29A1MEN1GAAMAPK1KMT2A | |
| SCHEMBL17817154 | 0.81 | SLC29A1 (0.67) | SLC29A1KMT2A | |
| SCHEMBL3301414 | 0.81 | SLC29A1 (0.51) | SLC29A1MEN1GAAMAPK1KMT2A | |
| SCHEMBL1033546 | 0.81 | CA1 (0.47) | SLC29A1MEN1GAAMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010066686-A2 | NOVEL TRIAZINE POLYMERS, METHOD FOR THE PRODUCTION AND USE THEREOF | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2010-06-17 | — | — | WO | claimed |
| EP-2268610-B1 | METHOD FOR PRODUCING A COMPOUND WITH AT LEAST ONE AT LEAST MONOSUBSTITUTED AMINO GROUP | BOREALIS AGROLINZ MELAMINE (AT) | 2016-08-03 | — | — | EP | disclosed |
| US-8871842-B2 | Method for producing a compound with at least one at least monosubstituted amino group | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2014-10-28 | — | — | US | disclosed |
| US-20110178212-A1 | Method for Producing a Compound with at Least One at Least Monosubstituted Amino Group | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2011-07-21 | — | — | US | disclosed |
| WO-2010066686-A2 | NOVEL TRIAZINE POLYMERS, METHOD FOR THE PRODUCTION AND USE THEREOF | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178212-A1 | Method for Producing a Compound with at Least One at Least Monosubstituted Amino Group | INMT, AADAT, AANAT | SLC29A1 1070/4885MEN1 380/4885GAA 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.